Novartis could sell Sandoz assets valued between USD 2bn - USD 3bn - report (translated)
08 JAN 2018
Novartis [VTX:NOVN], the Swiss pharmaceutical group, could sell parts of its US Sandoz business, Basler Zeitung reported. The Swiss daily said a Bloomberg article cited insiders who said Novartis is expanding its plan to sell US generic assets and could sell parts of its Sandoz business valued at USD 2bn to USD 3bn.
In December 2017, Novartis said it is planning the sale or discontinuation of certain non-core products, the report noted.
Pharma groups and private equity firms have already expressed an interest in Novartis' dermatology business, the report stated.
A Novartis spokesperson said the group continually examines the portfolio.